Barclays PLC Kal Vista Pharmaceuticals, Inc. Transaction History
Barclays PLC
- $353 Billion
- Q1 2025
A detailed history of Barclays PLC transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 55,227 shares of KALV stock, worth $641,185. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,227
Previous 68,062
18.86%
Holding current value
$641,185
Previous $577,000
10.57%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding KALV
# of Institutions
139Shares Held
54.4MCall Options Held
1.38MPut Options Held
6K-
Vr Adviser, LLC New York, NY6.7MShares$77.8 Million18.68% of portfolio
-
Tang Capital Management LLC San Diego, CA4.94MShares$57.4 Million3.7% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.91MShares$57 Million2.48% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA4.89MShares$56.7 Million3.55% of portfolio
-
Vestal Point Capital, LP New York, NY4.75MShares$55.2 Million3.92% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $286M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...